Research Study Summary
This study evaluates the long-term safety of Roflumilast in patients with chronic COPD. The medication is already available and on the market today.
$100 per visit for visits 1-8 and $50 for visit 9 and $15 for unscheduled visits. You may be reimbursed up to $25
Males and Females over the age 40 with a diagnosis of moderate or severe COPD. Other criteria may apply.
To Learn more
CW ID: 183341
Date Last Changed:
July 16, 2013
Clinical Trial Snapshot
- Both Male and Female
- 40 and up
- Overall Status
- 52 Weeks
- Facility Type
- $100 to $850
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.